Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Number of adverse events in those treated with sevasemten or placebo Measure: Severity of adverse events in those treated with sevasemten or placebo Measure: Change from Baseline in serum Creatine Kinase Measure: Change from Baseline in the North Star Ambulatory Assessment scale. After: Measure: Number of treatment emergent adverse events in those treated with sevasemten or placebo Measure: Severity of treatment emergent adverse events in those treated with sevasemten or placebo Measure: Change from Baseline in serum Creatine Kinase Measure: Change from Baseline in total North Star Ambulatory Assessment score.
Completion date type changed
Before: Estimated. After: Actual.
Primary completion date changed
Before: Sep 2026. After: 7 Sep 2026.
Recruitment status changed
Before: Active not recruiting. After: Completed.